Dolastatin 10
- Generic Name
- Dolastatin 10
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C42H68N6O6S
- CAS Number
- 110417-88-4
- Unique Ingredient Identifier
- EI946JT51X
- Background
Dolastatin 10 has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Liver Cancer, and Kidney Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00003778
- Locations
- ๐บ๐ธ
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธMayo Clinic Cancer Center, Rochester, Minnesota, United States
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
- Conditions
- First Posted Date
- 2004-08-17
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00003626
- Locations
- ๐บ๐ธ
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธUniversity of Colorado Cancer Center, Denver, Colorado, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-07-22
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 16
- Registration Number
- NCT00003557
- Locations
- ๐บ๐ธ
University of Illinois at Chicago, Chicago, Illinois, United States
๐บ๐ธLutheran General Cancer Care Center, Park Ridge, Illinois, United States
๐บ๐ธMichiana Hematology/Oncology P.C., South Bend, Indiana, United States
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2004-07-22
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT00003677
- Locations
- ๐บ๐ธ
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUniversity of Chicago Cancer Research Center, Chicago, Illinois, United States
Dolastatin 10 in Treating Patients With Advanced Kidney Cancer
- Conditions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT00003914
- Locations
- ๐บ๐ธ
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
๐บ๐ธMayo Clinic Cancer Center, Rochester, Minnesota, United States
๐บ๐ธMayo Clinic Jacksonville, Jacksonville, Florida, United States
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
- First Posted Date
- 2004-03-23
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003693
- Locations
- ๐บ๐ธ
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- University of Vermont
- Registration Number
- NCT00005579
- Locations
- ๐บ๐ธ
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
๐บ๐ธArthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
๐บ๐ธBarbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.